Comparative Pharmacology
Head-to-head clinical analysis: FESOTERODINE FUMARATE versus GLYCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FESOTERODINE FUMARATE versus GLYCORT.
FESOTERODINE FUMARATE vs GLYCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), with highest affinity for M3 receptors; reduces detrusor muscle contractions and bladder overactivity.
Glucocorticoid receptor agonist; modulates gene expression to produce anti-inflammatory and immunosuppressive effects.
4 mg orally once daily; may be increased to 8 mg once daily based on tolerability.
Intravenous: 2 mg/kg every 12 hours; Oral: 20 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5–10 hours) for the active metabolite (5-hydroxymethyl tolterodine, 5-HMT). The parent drug fesoterodine has a very short half-life (<1 hour) and is rapidly hydrolyzed to 5-HMT. Clinical context: steady-state achieved within 2–4 days of b.i.d. dosing.
3.5 hours (terminal); prolonged in hepatic impairment (up to 8 hours) and severe renal impairment (up to 6 hours)
Primary route is renal (70% of administered dose as metabolites, 7% as unchanged drug). Hepatic metabolism with biliary/fecal elimination accounts for ~23% (primarily via CYP2D6 and CYP3A4).<|im_end|>
Renal: 70% as unchanged drug; biliary/fecal: 25% (metabolites); 5% other
Category A/B
Category C
Anticholinergic
Anticholinergic